Levine Cancer Institute Financial Toxicity Tumor Board: A Potential Solution to an Emerging Problem

JCO Oncol Pract. 2021 Oct;17(10):e1433-e1439. doi: 10.1200/OP.21.00124. Epub 2021 Jun 8.

Abstract

Purpose: Fiscal distress or "financial toxicity," in which patients experience challenges in paying for treatment, are becoming dominant problems for patients with cancer because of burgeoning health care costs and strategies implemented by health insurance payers to reduce their level of expenditure. We report the structure and function of the first Financial Toxicity Tumor Board (FTTB). Modeled on the concept of a conventional multidisciplinary tumor board, FTTB functions as a multidisciplinary conference providing broad problem-solving approaches to financial toxicity.

Methods: The FTTB, with participation from physicians, nurses, financial counselors, nurse navigators, social workers, and administrators, meets monthly and is focused on financial toxicity and financial worry experienced by patients with cancer. It is linked to a Patient Assistance Program for oncologic pharmaceutical agents as this domain constitutes a critical area of financial toxicity for many patients.

Results: In the first years of function, more than $55-$60 million of personal expenditure has been avoided for 1,749 and 1,819 patients, respectively, as well as more than $1.3 million copay assistance provided for financially challenged patients. Problems addressed have included payer impediments, underinsurance, complexities of certification, coding or billing issues, and inadequate internal standard operating procedures.

Conclusion: A focus on proactive management of financial toxicity through the function of multidisciplinary FTTBs substantially ameliorates this burgeoning international problem. This concept is presented early as it may be leveraged readily in other centers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Health Care Costs
  • Health Expenditures
  • Humans
  • Insurance, Health
  • Medical Oncology*
  • Neoplasms* / drug therapy